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Abstract
Background: Colonoscopy is an invasive and costly procedure with a risk of serious complications. It would
therefore be useful to prioritise colonoscopies by identifying people at higher risk of either cancer or premalignant
adenomas. The aim of this study is to assess a model that identifies people with colorectal cancer, advanced, large
and small adenomas.
Methods: Patients seen by gastroenterologists and colorectal surgeons between April 2004 and December 2006
completed a validated, structured self-administered questionnaire prior to colonoscopy. Information was collected
on symptoms, demographics and medical history. Multinomial logistic regression was used to simultaneously
assess factors associated with findings on colonoscopy of cancer, advanced adenomas and adenomas sized 6 -9
mm, and ≤ 5 mm. The area under the curve of ROC curve was used to assess the incremental gain of adding
demographic variables, medical history and symptoms (in that order) to a base model that included only age.
Results: Sociodemographic variables, medical history and symptoms (from 8,204 patients) jointly provide good
discrimination between colorectal cancer and no abnormality (AUC 0.83), but discriminate less well between
adenomas and no abnormality (AUC advanced adenoma 0.70; other adenomas 0.67). Age is the dominant risk
factor for cancer and adenomas of all sizes. Having a colonoscopy within the last 10 years confers protection for
cancers and advanced adenomas.
Conclusions: Our models provide guidance about which factors can assist in identifying people at higher risk of
disease using easily elicited information. This would allow colonoscopy to be prioritised for those for whom it
would be of most benefit.
Background
The majority of colorectal cancer cases are still diagnosed
in a clinical setting, even in countries offering screening
[1]. Early detection of colorectal cancer reduces both the
cancer mortality [2-7] and the incidence [6,8] of the dis-
ease. The reduction in incidence is thought to be due to
removal at colonoscopy of adenomas which are recog-
nised as non-obligate precursor lesions to cancer [9].
Adenomas are commonly found in adults over 50 years
undergoing colonoscopy, and the majority of these will
not develop into cancer. The malignant potential of an
adenoma depends on its size and histology, with larger
adenomas and those with more than 25% villous archi-
tecture or dysplasia more likely to have a higher risk.
Church has estimated that 16% of adenomas between 6-9
mm and 4% of those between 1-5 mm fit into this higher
risk category based on their histology [10].
Colonoscopy is an invasive and costly procedure: ser-
ious complications, including bleeding and bowel per-
foration may occur in 0.1-0.6% of procedures [11-13].
Further, colonoscopy is a scarce resource. The Center
for Disease Control and Prevention (CDC) in the United
States has shown that even if half the colonoscopy capa-
city was dedicated to screening, the capacity to under-
take such screening would be limited [14]. It would
therefore be useful to be able to select people for colo-
noscopy who at higher risk of either cancer or premalig-
nant adenomas.
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predictors of the presence of colorectal cancer but that
prediction improved using a model which also included
demographic details and medical history such as previous
colonoscopy, bowel disease, smoking history, and use of
aspirin or non steroidal anti-inflammatory medications
[15]. Advanced adenomas were excluded from that analy-
sis. The aim of this current paper is to report the results
of a more comprehensive model that discriminates
between colorectal cancer, advanced adenoma, large ade-
nomas and small adenomas (versus none of these
abnormalities).
Methods
The study design and inclusion criteria have been
described previously [15]. This is a cross sectional study
in which participating patients (> 18 years, and recruited
from participating gastroenterologists and colorectal sur-
geons following scheduling for colonoscopy for any indi-
cation) completed a questionnaire, previously shown to
be reliable and reproducible [16], eliciting details about
demographic details, family history, medical history (pre-
vious colonoscopy and bowel disease, polyps, aspirin and
NSAID use within the previous 2 years, smoking history),
and bowel symptoms. These included rectal bleeding,
change in bowel habit, passage of rectal mucus, abdom-
inal or anal pain, sensation of abdominal or anal lump,
incomplete evacuation, urgency, history of anaemia,
weight loss, and fatigue. We also elicited information
about characteristics of the symptom such as duration,
frequency and severity and whether or not the patients
had sought consultation with a doctor for that symptom.
Findings at colonoscopy were obtained from endoscopic
records. All lesions found were confirmed by histological
examination. We classified findings into five categories:
cancer, advanced adenoma (adenoma with significant
(> 25%) villous features, or high grade dysplasia, including
carcinoma-in-situ, or size 10 mm or larger [17,18], adeno-
mas 6 to 9 mm in size, adenomas ≤ 5m m ,a n dn oa d e -
noma found. Where patients had more than one lesion,
we classified them by their most significant lesion, accord-
ing to the hierarchy listed above. If the adenoma size was
not recorded by the endoscopist, we used the size
recorded at histological examination; if neither of these
was available, we used the size description noted by the
endoscopist (based on analysis of adenomas for which we
had both the description and size reported, we categorised
descriptions of “diminutive”, “tiny”, “very small”,o r
“minor” as ≤ 5m m ;“moderate” or “small” as 6-9 mm; and
“large”, “very large”,o r“huge” as ≥ 10 mm). We classified
adenomas for which no size was recorded as ≤ 5m m
(n = 32).
Patients were recruited between April 2004 and
December 2006. We included only patients who
completed the questionnaire 6 months or less before
their colonoscopy was done, and whose colon examina-
tion was complete (visualisation of the caecal pole at
colonoscopy or if not visualised, by follow up bowel
investigations).
Ethics committee approval
The study received approval from the Ethics Commit-
tees of the University of Sydney, Central Sydney (CRGH
and Central Zones), Northern Sydney and Central
Coast, and Western Sydney Area Health Services and
the Sydney Adventist Hospital. All patients provided
written consent.
Statistical Analysis
Patients were grouped according to the most significant
grade of abnormality found giving five different outcome
groups: cancer, advanced adenomas, adenomas of size 6 to
9 mm, adenomas of size ≤ 5 mm, and no cancer or any
adenomas. Descriptive analyses were undertaken to assess
the prevalence of cancer, advanced adenomas and smaller
adenomas separately by demographic, medical history and
symptom variables using the sum of no abnormality and
the outcome of interest only as the denominator. Odds
ratios were calculated comparing the odds of having
cancer, advanced adenoma or adenomas 6-9 mm or
≤ 5 mm (separately for each of these outcomes) with no
abnormality univariately for each of the symptom, demo-
graphic and other health information subgroups. Multino-
mial logistic regression was then used to simultaneously
assess which of these risk factors were associated with the
outcomes of cancer, advanced adenomas and adenomas
sized 6 - 9 mm, and ≤ 5 mm. This method fits simulta-
neous logistic regression models, each with its own inter-
cept and coefficients, to compare each of the four
outcomes listed above to the referent category (no cancer,
advanced adenoma or adenoma of any size). Backwards
elimination of risk factors was used to simplify the model
using likelihood ratio tests with p < 0·05 as the criterion
for statistical significance. Interactions were considered for
elimination first. As numerous comparisons were made,
results for interactions were not included if their signifi-
cance was close to 0·05 and there was no biologically plau-
sible basis for the interaction. Because the estimated
coefficients for the explanatory variables vary by outcome,
odds ratios for the final model were calculated for each
risk factor (compared to not having the risk factor) for
each outcome of cancer, advanced adenoma and adenoma
o fa n ys i z eu s i n gt h ea b s e n c eo ft h e s ea st h er e f e r e n c e
group. This analysis for the cancer outcome differs slightly
from that reported previously [15] as the comparison
group in that paper included adenomas less than 10 mm
in the referent group, whereas this analysis uses no
abnormality as the referent group.
Adelstein et al. BMC Gastroenterology 2011, 11:97
http://www.biomedcentral.com/1471-230X/11/97
Page 2 of 10A sequence of additional multinomial logistic regres-
sion models were fitted to assess the incremental value of
variables found to be statistically significant in the final
model. The sequence was: (1) age only; (2) model 1 +
other demographic variables; (3) model 2 + medical his-
tory variables; (4, the final model) model 3 + symptoms.
For each of the four outcomes, estimates of sensitivity
and specificity across all values of predicted probability,
with no abnormality (ie no cancer, advanced adenoma or
adenomas) as the referent group common to all, were
used to obtain a ROC curve. The area under each curve
was used to assess the ability of the model to discriminate
between patients with no abnormality and patients with
(i) adenomas ≤ 5 mm; (ii) adenomas 6 - 9 mm; (iii)
advanced adenomas and (iv) cancer.
The percent of abnormalities that would have been
detected was calculated for different possible screening
criteria based on age and previous colonoscopy. To allow
comparison with the model, the predicted probabilities of
cancer were sorted from highest to lowest and a cut-
point was applied to include the same number of patients
(above the cut-point) who would have been screened
based on the age and previous colonoscopy criteria.
Detection rates for cancer and adenomas were then com-
pared. Detection rates for the 40% of patients with the
highest predicted probability of cancer from the model
were also computed. All analyses were done in SAS
version 9.2.
Results
Data were available from a total of 8,204 patients. 47%
were male. The age range was 18 to 95 years (median age
58 years), with 27% aged less than 50 years, 26% 50-59
years, 25% 60-69 years and 22% over 70 years of age. All
patients underwent colonoscopy, for which there was a
98% caecal intubation rate. The overall cancer prevalence
was 1.9% (159 patients). Risk of cancer and adenomas was
dependent on age (Figure 1). The prevalence of cancer
and all types of adenomas ranged from less than 3% in
people under 50 years of age, and increased to over 10% in
people 70 years or older for advanced adenoma. The odds
ratios, which measure the increase in prevalence as age
increases relative to people under 50 was strongest for
cancers, and similar for all types of adenomas.
59% had undergone colonoscopy in the previous 10
years. Cancer rates were approximately 5 times greater in
patients who had not had a previous colonoscopy in each
age group, whereas advanced adenoma rates were about
twice as high in people who had not had a colonoscopy in
each age group (Table 1). For smaller adenomas (less than
10 mm), there was no clear pattern related to prior
colonoscopy.
The relative prevalence of abnormalities increased
with age in a similar way for those who had or had not
had a previous colonoscopy. For instance, in people who
have had a previous colonoscopy, the cancer rate in
people aged 70 or more was 17 times higher than in
people aged less than 50 (from Table 1, 17/1000 divided
by 1/1000). The estimate in people who have not had a
previous colonoscopy in the previous 10 years was 12.3
(from Table 1, 74/1000 divided by 6/1000). The corre-
sponding estimates for: advanced adenoma were 4.1 vs
3.8; adenomas 6-10 mm were 2.9 vs 2.9; adenomas ≤ 5
mm were 2.5 vs 4.7 respectively. There is no statistical
evidence (p = 0.51) that the effect of age was modified
by previous colonoscopy which indicates that the
observed variability is due to chance. Furthermore, the
predicted rates per 1000 based on a multinomial model
(see additional file 1) that included age and previous
colonoscopy as predictor variables are very similar to
the observed rates in Table 1, indicating that even with
only these two variables the model fits well.
The fact that the model with the 2 major predictors,
age and previous colonoscopy, fits the data well suggests
that the appropriate way to assess the value of potential
risk factors is to assess whether adding them to this mul-
tivariable model results in any improvement to the fit.
Further model checks showed that the odds ratios for all
predictors were very similar in the model that included
all additional significant variables, when run separately
for people with or without previous colonoscopy (addi-
tional file 1). Similarly, statistical tests for interaction
indicated that neither previous colonoscopy nor age were
effect modifiers for the other variables subsequently
included in the model.
Multivariable risk identification
The results of the multivariable model to distinguish
between each outcome and the absence of cancer or any
adenoma (the referent category) are shown in Table 2.
The effect of age followed a similar pattern to that in
Figure 1. For cancer and all types of adenomas, male gen-
der increased the risk by about a third. Colonoscopy in the
last 10 years remained highly protective for cancer, but the
effect became far less marked the smaller the adenoma.
With previous colonoscopy in the model, a history of ade-
nomas was not predictive of cancer, but was predictive of
finding adenomas again. There was an exposure response
relationship between amount of tobacco smoked and can-
cer. For adenomas, the gradient of the exposure-response
was less steep, and became flatter the smaller the size of
the adenoma. A self reported history of irritable bowel
syndrome, and of NSAID or aspirin use was associated
with reduced cancer risk but the effect on adenomas was
weaker or absent. For symptoms, a history of passing
mucus per rectum and rectal bleeding were associated
with a higher risk of cancer, particularly if the symptom
was of recent onset and occurred frequently. This
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with the possible exception of bleeding with advanced
adenomas.
The areas under the ROC curves based on the predic-
tive models for cancer and adenomas are shown in
Figure 2 and Table 3. With only age in the model, the
areas were 0.66 for cancer and between 0.60 and 0.62
for adenomas indicating moderate discrimination. As
other sociodemographic variables, medical history and
symptoms were added, the area under the curve for
Figure 1 Colorectal cancer and adenomas: prevalence and risk of different age groups. The prevalence (with 95% confidence interval) of
cancer, advanced adenomas and adenomas (≤5 mm and 6 - 9 mm) for each age group (less than 50 years, 50 - 59 years, 60 - 69 years and
more than 70 years) and the odds ratio (with 95% confidence interval) of having cancer, advanced adenomas and adenomas for the age groups
50 - 59 years, 60 - 69 years and more than 70 years compared to those less than 50 years. 6784 patients had no cancer, advanced adenomas or
adenomas, 507 had adenomas ≤ 5 mm, 286 had adenomas 6 - 9 mm, 468 had advanced adenomas and 159 had cancer.
Table 1 Rates (per 1,000) of cancers and adenomas by age and colonoscopy in previous 10 years
Cancer
n = 159
Advanced Adenoma
n = 468
Adenoma 6 - 10 mm
n = 286
Adenoma ≤ 5m m
n = 507
No abnormality
n = 6784
Age Group (years) Cpy
yes
Cpy
no
Cpy
yes
Cpy
no
Cpy
yes
Cpy
no
Cpy
yes
Cpy
no
Cpy
yes
Cpy
no
≤50 1 6 19 29 20 18 38 19 922 928
50 - 59 4 31 35 74 33 33 60 63 867 800
60 - 69 11 48 54 93 34 39 84 60 817 760
≥70 17 74 78 109 57 53 94 90 754 674
Total 9 31 50 66 38 31 73 49 831 822
Cpy = colonoscopy in previous 10 years
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Page 4 of 10Table 2 Multinomial model odds ratios for the included demographic/medical history and symptom variables for each of the four outcomes compared to
patients with no adenomas, advanced adenomas or cancers
Cancer
(n = 159)
Advanced Adenoma
(n = 468)
Adenoma
Size 6 - 9 mm
(n = 286)
Adenoma
Size ≤ 5m m
(n = 507)
n % OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) p-value
DEMOGRAPHIC/MEDICAL HISTORY
Age < 50 years (Reference) 2211 27.0
50 - 59 2169 26.4 6.84 (3.33, 14.06) ** 2.54 (1.82, 3.55) ** 1.72 (1.15, 2.55)** 2.36 (1.70, 3.26)** <.001
60 - 69 2032 24.8 13.84 (6.77, 28.29) ** 3.47 (2.48, 4.87) ** 1.79 (1.19, 2.70) ** 2.74 (1.97, 3.82)**
70 or more 1792 21.8 23.54 (11.43, 48.45) ** 5.27 (3.72, 7.47) ** 2.99 (1.98, 4.52) ** 3.60 (2.55, 5.07) **
Gender Female (Reference) 4344 52.9
Male 3860 47.1 1.44 (1.02, 2.04)* 1.29 (1.05, 1.57)* 1.53 (1.19, 1.96)** 1.37 (1.13, 1.65)** <.001
Colonoscopy None in last 10 years (Reference) 3791 46.2
Previous (in last 10 years) 4413 53.8 0.22 (0.15, 0.34) ** 0.42 (0.33, 0.53) ** 0.71 (0.53, 0.95)* 0.87 (0.70, 1.09) <.001
History of colorectal polyps No (reference) 6436 78.4
Yes 1768 21.6 0.87 (0.47, 1.59) 1.99 (1.53, 2.58) ** 1.89 (1.39, 2.56) ** 1.79 (1.43, 2.25) ** <.001
Smoking Status Non-smoker (Reference) 4710 57.4
4 or less pack years 1246 15.2 0.89 (0.52, 1.55) 0.95 (0.70, 1.30) 0.75 (0.51, 1.12) 0.89 (0.67, 1.19) 0.010
4 to 15.5 pack years 1188 14.5 1.49 (0.95, 2.33) 1.43 (1.09, 1.86) ** 1.04 (0.74, 1.48) 0.95 (0.73, 1.25)
more than 15.5 pack years 1060 12.9 1.52 (0.98, 2.37) 1.53 (1.17, 2.00) ** 1.40 (1.01, 1.93)* 1.11 (0.85, 1.45)
History of irritable bowel syndrome No (Reference) 7240 88.2
Yes 964 11.8 0.45 (0.21, 0.99)* 0.45 (0.29, 0.70) ** 0.98 (0.66, 1.45) 0.95 (0.71, 1.29) 0.001
History of NSAID use No (Reference) 7445 90.7
Yes 759 9.3 0.33 (0.15, 0.72) ** 0.42 (0.28, 0.65) ** 0.80 (0.52, 1.22) 0.69 (0.49, 0.97)* <.001
History of aspirin use No (Reference) 6874 83.8
Yes 1330 16.2 0.54 (0.34, 0.85) ** 0.79 (0.61, 1.02) 1.09 (0.81, 1.48) 0.94 (0.74, 1.20) 0.023
Education Level Secondary or lower (Reference) 3721 45.4
Tertiary 4483 54.6 0.83 (0.59, 1.17) 0.81 (0.67, 0.99)* 1.03 (0.81, 1.33) 0.80 (0.66, 0.97)* 0.044
SYMPTOMS
Bleeding No Symptom (Reference) 5181 63.2
no other info 64 0.8 2.35 (0.67, 8.18) 0.51 (0.12, 2.16) 1.52 (0.53, 4.31) 0.22 (0.03, 1.60) <.001
present greater 12 months 1044 12.7 1.25 (0.68, 2.33) 1.39 (1.03, 1.88)* 0.67 (0.42, 1.05) 1.04 (0.77, 1.40)
Occurring monthly or occasionally;
and present less 12 months
1226 14.9 2.00 (1.26, 3.17) ** 1.21 (0.92, 1.60) 1.08 (0.77, 1.52) 1.08 (0.83, 1.42)
weekly; present less 12 months 689 8.4 5.09 (3.26, 7.94) ** 1.43 (1.00, 2.03) 0.80 (0.47, 1.36) 0.58 (0.36, 0.93)*
Mucus No Symptom (Reference) 6886 83.9
no other info 131 1.6 0.43 (0.06, 3.24) 1.01 (0.43, 2.37) 0.27 (0.04, 1.96) 0.55 (0.20, 1.51) 0.001
present greater 12 months 466 5.7 1.10 (0.43, 2.79) 0.69 (0.39, 1.20) 0.69 (0.35, 1.37) 0.60 (0.36, 1.02)
Occurring monthly or occasionally;
and present less 12 months
393 4.8 1.37 (0.66, 2.84) 0.82 (0.48, 1.42) 1.71 (1.04, 2.82)* 0.99 (0.62, 1.60)
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0Table 2 Multinomial model odds ratios for the included demographic/medical history and symptom variables for each of the four outcomes compared to
patients with no adenomas, advanced adenomas or cancers (Continued)
Weekly; present less 12 months 328 4.0 3.00 (1.71, 5.25) ** 0.99 (0.57, 1.72) 0.46 (0.17, 1.26) 0.35 (0.14, 0.85)*
Anaemia No (Reference) 7383 90.0
Yes 821 10.0 2.95 (1.96, 4.45) ** 0.84 (0.59, 1.21) 0.55 (0.32, 0.94)* 0.76 (0.54, 1.09) <.001
Fatigue No (Reference) 4938 60.2
Yes 3266 39.8 1.36 (0.97, 1.91) 0.67 (0.54, 0.83) ** 0.80 (0.62, 1.04) 0.90 (0.74, 1.10) <.001
Total number of patients 8204; number with no abnormality 6784.
Key ORs in bold are statistically significant
* p 0.01 - 0.05
** p < 0.01
A
d
e
l
s
t
e
i
n
e
t
a
l
.
B
M
C
G
a
s
t
r
o
e
n
t
e
r
o
l
o
g
y
2
0
1
1
,
1
1
:
9
7
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
3
0
X
/
1
1
/
9
7
P
a
g
e
6
o
f
1
0cancer achieved good discrimination (0.83), but the
improvement for advanced adenomas and smaller ade-
nomas was less marked (0.70 and 0.67 respectively).
Using the multivariable model (which includes age,
sociodemographic variables and symptoms), the pre-
dicted probability for an individual can be calculated for
each of the outcomes, based on age and gender, medical
history and symptoms. The value of the model can be
demonstrated by comparing the model results with sim-
ple methods for predicting risk (Table 4). For example, if
we restricted colonoscopies to people 40 years and older,
we would have avoided 10.5% of colonoscopies but still
detected all of the cancers and over 97% of the adenomas.
If we use the model to avoid colonoscopy in the 10.5% at
lowest cancer risk, we would have missed 1.3% of the
cancers. So for low-risk patients, a simple age-based
method does well. For high-risk patients defined for
example as people 60 years and older who have not had a
colonoscopy in the past 10 years: 16% of the population
are in this group but it contains almost half of the can-
cers (49.1%) and 28% of the advanced adenomas. If we
examine instead the 16% at highest risk from the model,
the cancer detection rate increases to 64.8%, without any
loss in adenoma detection. In fact 85.5% of the cancers
and 57.7% of the adenomas could be detected by the
model by only performing colonoscopy on the 40% iden-
tified by the model as being at highest risk.
Discussion
Our findings demonstrate that a predictive model based
on sociodemographic variables (age, gender and educa-
tion level), pertinent medical history (previous colono-
scopy, smoking, use of NSAID or aspirin, previous
polyps, and IBS) and symptoms (rectal bleeding, rectal
mucus, anaemia and fatigue), does well at predicting
colorectal cancer and reasonably well at predicting
advanced adenomas.
It is of interest to identify which variables are most
strongly predictive of cancer and adenoma prevalence.
Age is the dominant risk factor for cancer and for adeno-
mas of all sizes. Having had a colonoscopy within the
previous 10 years confers protection for cancers and
advanced adenomas. Adding medical history and symp-
toms (rectal bleeding, mucus, anaemia and fatigue) to the
model adds further modest improvement to cancer
prediction, but negligible improvement to adenoma
prediction.
Our finding that family history is not associated with an
increase in prevalence of colorectal cancer may seem sur-
prising. It is likely that this reflects the clinical setting of
our cohort, with patients with a family history of colorectal
cancer already having been screened and included in those
having undergone colonoscopy previously. Other studies
have also noted that in people with symptoms a positive
False positive rate
T
r
u
e
 
p
o
s
i
t
i
v
e
 
r
a
t
e
0.0 0.2 0.4 0.6 0.8 1.0
0
.
0
0
.
2
0
.
4
0
.
6
0
.
8
1
.
0
Cancer
Advanced Adenomas
Adenomas 6 − 9mm
Adenomas <= 5mm
Figure 2 ROC curves for the multinomial model showing the
discrimination of the model for cancer, advanced adenomas
and adenomas sized 5 - 9 mm and ≤ 5 mm; for each outcome
the reference group is no cancer, advanced adenoma, or
adenomas.
Table 3 Areas under the curve for multivariable prediction of cancer and adenomas
Cancer Advanced Adenoma Adenomas
6-9m m
Adenomas
≤5m m
Model 1:
Age
0.66 0.62 0.60 0.62
Model 2:
Model 1 + gender, previous colonoscopy, education level
0.77 0.66 0.62 0.64
Model 3:
Model 2 + history of: smoking, IBS, adenomas, or NSAID, aspirin use
0.79 0.69 0.65 0.66
Model 4:
Model 3 + symptoms*
0.83 0.70 0.67 0.67
Note: NSAID = non- steroidal anti-inflammatory drug
IBS = irritable bowel syndrome
*only bleeding, rectal mucus, anaemia and fatigue were found to be significant and included in the final model.
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[19,20], and indeed, guidelines for referral of patients in
place in Britain which aim to identify patients with higher
risk symptoms, do not include assessment of family history
[21].
The quality of our study relates to several factors
including the size of our study with over 8,000 patients,
the prospective nature of the data collection, the comple-
teness of information on all patients, the requirements of
complete examination of the entire colon, and pathologi-
cal examination of all lesions encountered. Information
about symptoms was also consistently collected using a
validated questionnaire [16]. A further strength of our
study is that it represents a heterogeneous population
which reflects what occurs in clinical practice in the real
world and allows exploration of what factors that make
up that heterogeneity predict the probability of cancer or
adenomas. A potential limitation of our study was that
there was no standard reporting for colonoscopy. How-
ever, the reports from which data were extracted were
those used in clinical practice; based on a caecal intuba-
tion rate of 98% we believe the procedures were of high
quality.
Our model does well at predicting cancer prevalence,
achieving an area under the ROC curve of 0.83 which is
similar to that found in other studies, for example Selva-
chandran (0.86) [22]. Our models help to identify indivi-
duals who have a high probability of cancer amongst
people referred to gastroenterologists and colorectal
surgeons, thus helping to indicate the urgency for colono-
scopy. At the low-risk end of the spectrum, prediction can
be simplified to age: the probability of cancer or adenoma
is very low in people under 40 and reduced still further if
they have had a colonoscopy in the previous 10 years. For
them, potential risks of colonoscopy may outweigh poten-
tial benefits. Consideration can be given to discussing ben-
efits and harms of the procedure with patients to reach
the best benefit-harm trade-off for each person, as has
been done in other areas of health care [23].
In addition, risk information from the model can be use-
ful at a policy level. Decision making about resource utili-
sation at a population level should take risk assessment
into account to ensure that colonoscopy is prioritised to
groups at higher risk of disease. At a general practice level,
resources may, for example be directed to ensure that
those in higher risk groups are referred for colonoscopy,
while at a specialist level resources should be targeted at
those who have never had a colonoscopy rather than for
inappropriate, frequent colonoscopy. At a population level,
symptoms as warnings for cancer or adenomas should be
de-emphasised. Our model is not strictly applicable to
patients presenting to a general practice. However, it is
not feasible to do a study in patients presenting to a gen-
eral practitioner and obtain colonoscopies on all patients.
Indeed, the major symptom prediction studies in patients
have been done in referred populations [22,24,25]. Our
cancer prevalence is considerably lower (1.9%) than in
other similar studies, which report cancer prevalences of
between 4 to 12% [22,24-26], suggesting that our popula-
tion is less strongly filtered and therefore more representa-
tive of general practice.
In addition, given that in general practice the probability
of cancer may be even lower than that predicted in the
referred population, it seems reasonable to use the infor-
mation from the model to inform decisions in general
practice, in particular to identify who has a very low prob-
ability of cancer or advanced adenoma. The model will be
the most reliable source of predicting cancer or advanced
adenoma for most patient characteristics. This can be sup-
plemented with selected information, for example the
effect of family history, from sources where that has been
reliably estimated elsewhere.
Another approach to identifying patients at higher risk
for cancer or adenomas on colonoscopy patients is to use
FOBTs [2-5], as suggested by Rozen [27]. A recent review
of FOBTs provided odds ratios for FOBT detection of can-
cer and advanced adenoma, which can be converted to
areas under the ROC curve (AUC) and compared with
our model [28]. The AUC values were 0.93 for cancer,
0.88 for advanced adenomas and 0.69 for all adenomas.
Other AUC values obtained for adenomas in a clinically
presenting population were 0.72 for advanced adenomas
and 0.64 for all adenomas. Overall, these are similar to or
slightly higher than those found in our study. These data
might suggest that FOBT would be as, or more, effective
than our model as a triage tool for prioritising colono-
scopy. However, FOBT requires additional cost and effort,
whereas our model requires only easily and immediately
Table 4 Outcome (percentage) that would have been detected using the model if colonoscopy restricted
Group to which colonoscopy restricted Cancer
(%)
Advanced Adenoma
(%)
Adenomas
6-9m m
(%)
Adenomas ≤ 5m m
(%)
Aged 40+ (89.5% of patients) 100.0 97.0 97.2 97.4
Top 89.5% predicted probability of cancer from model 98.7 96.8 93.0 92.5
Aged 60+ and no previous colonoscopy (16% of patients) 49.1 28.2 20.6 18.9
Top 16% predicted probability of cancer from model 64.8 28.2 16.8 17.8
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tion. Models that incorporate both this information and
FOBT results should be developed and evaluated as this
may boost prediction still further.
Conclusions
Colorectal cancer is common and preventable. Our mod-
els may assist in identifying population subgroups at
higher risk of disease, ensuring that colonoscopy is priori-
tised for those for whom it would be of most benefit. Age
is the dominant risk factor in this model. Younger age and
prior colonoscopy in the preceding 10 years predicts a low
probability of cancer or adenomas and should be appre-
ciated by referrers, proceduralists, providers and health
planners when aiming to target colonoscopy resources
most effectively.
Additional material
Additional file 1: Table 1: Multinomial model results from two
separate models for 1) those patients who have had a colonoscopy
in the last 10 years, and 2) those patients who have not. Table
showing odds ratios for each variable in the multinomial model for
cancer, advanced adenoma, adenomas 6-9 mm, and adenomas ≤ 5 mm,
shown for patients who have had a colonoscopy in the last 10 years and
for those who have not.
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